[Biotech company Tempest skyrocketed 3,972%! New data confirms positive results for liver cancer therapy] On Wednesday, Tempest Therapeutics, Inc., a clinical-stage oncology company. Shares surged 3,972.53 percent to $9.77. Today, Tempest announced the results of the latest positive data obtained in the clinical trial of its development "TPST-1120". TPST-1120 is an oral, selective PPARα small molecule antagonist. Data from a globally randomized Phase 1b/2 clinical trial published in April this year showed that TPST-1120 showed significant improvement in objective response rate (ORR) and demonstrated a favorable safety profile in first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).